Why Big Pharma Won’t Fund Cures It Can’t Patent: Tony Huge’s Video Guide
If a compound shows real promise in the research, why doesn’t it become a medicine? Most people assume the answer is about safety or whether it works. Tony Huge’s video argues that Big Pharma applies a second filter that has almost nothing to do with the science: patents. He walks through what drug approval costs, why a company will only pay it for something it can own, and why that leaves an entire category of unpatentable compounds stuck in what health economists call the valley of death. Then he does something unusual for this genre. He tells you how to spot when a real economic fact is being dressed up as a conspiracy.
MK-677 Grogginess Explained: The Sleep Study Nobody Cites Right: Tony Huge’s Video Guide
MK-677 grogginess is the complaint Tony Huge hears most, and plenty of people quit over it. His answer in this video is that the grogginess is not a malfunction. It is the compound doing the one thing it is supposed to do. He walks through the 24-hour growth hormone pulse, the 1997 electrode sleep study that almost every health site misquotes, and the reason a middle-aged man on a growth hormone secretagogue starts wanting sleep the way a teenager does.
Steroids Ruined These Bodybuilders? What the Montage Left Out: Tony Huge’s Video Guide
A viral montage shows legendary bodybuilders at their peak, then the worst photo anyone can find from later in life, and blames the difference on steroids. Tony Huge reacts to it frame by frame. His argument is not that steroids are harmless. It is that a before and after picture cannot tell you what caused the change, and that the benefits those men actually received keep getting deleted from the story.
My Hematocrit Hit 59% on TRT: Tony Huge’s Video Guide
Tony Huge’s hematocrit came back at 59%. That number is the headline, but the video is really about the trade nobody explains when they tell a man on testosterone to go donate blood. The draw fixes thickness this month and quietly drains iron all year, and Tony argues you cannot manage one without watching the other.
Does TRT Cause Hair Loss? Gel vs Injections vs Enclomiphene: Tony Huge’s Video Guide
Tony Huge has run testosterone for 14 years and still has his hair, and this video is his attempt to explain why that might not be luck. His answer to the TRT hair loss question is that male pattern baldness is a DHT problem rather than a testosterone problem, which means the route you use to raise testosterone matters more than the number you land on. He compares gel, injections, and enclomiphene on one metric, how much DHT each one generates per unit of testosterone, and then tells you exactly where the hormone data ends and the guesswork begins.
Smellmaxxing and 2-Nonenal: The Science of Old People Smell: Tony Huge’s Video Guide
Tony Huge has spent years reversing his biological age, and then a girlfriend told him he smelled old. This video is what he found: a molecule called 2-nonenal that shows up on skin after about 40, a discovery paper written by the company that had already patented the fix, an independent study that flips the story, and a grade for every claimed remedy. He calls it smellmaxxing, and most of the industry advice fails his ladder.
Can Enclomiphene Get Testosterone Over 1,000? Tony Huge’s Video Guide
More than 1,100 men have been through enclomiphene trials, and exactly one of those trials ever counted how many blood samples crossed 1,000 ng/dL. What it printed is not what anyone online is quoting. Tony Huge goes through every published record of enclomiphene testosterone levels, the registry postings, and the sponsor’s own tables, and ends up with a different question: why did a company that drew blood every hour for 24 hours stop counting at 500?
BPC-157 Explained: Rat Studies, Human Data and Trade-Offs: Tony Huge’s Video Guide
BPC-157 has zero completed human trials, and Tony Huge uses it anyway. When he eats wheat his gut normally takes five days or more to recover; on BPC-157 it takes one or two, every time, across roughly 60 repetitions. This video is about holding both facts at once: the rat literature that built the peptide’s reputation, the very short list of human evidence, the regulatory gray zone, and how to read your own results without fooling yourself.
Does RAD 140 Build Muscle? What the Research Says: Tony Huge’s Video Guide
The biggest myth about RAD 140 is that it has never been tested in a human. It has, but the trial was in 22 women with advanced breast cancer, and it measured receptor activity and liver markers, not how much muscle a trained man can add. Tony Huge walks through that study, the 2025 rat data, the mouse frailty findings, and the LGD-4033 suppression trial to show what the research does and does not answer.
Tesamorelin Exposed: Same Growth Hormone, Different Doorway: Tony Huge’s Video Guide
Tesamorelin does one thing: it raises your own growth hormone. Everything it does to visceral fat, it does through that hormone, and the FDA label says so. Tony Huge’s argument in this video is that if growth hormone is the whole mechanism, then the molecule that released it is interchangeable, and the tesamorelin vs ipamorelin comparison is his worked example: a peptide costing a tenth as much that also releases growth hormone in pulses deserves the same credit. He walks the label, the fat-cell biology, the pivotal trial, the strongest counterargument, and the money, and then says plainly where sound reasoning stops being a trial.